Restore Vision's Latest Funding Boost

Restore Vision, a Japanese startup focused on developing gene therapy for visual restoration, has successfully raised ¥1.3 billion in its Pre-Series B funding round. The company, led by CEO Yusaku Katada, is advancing its innovative approach to treating retinal diseases using gene therapy.

Investors and Funding Details

The funding round saw participation from several prominent investors, including Higo Bank Capital, Kyoto University Innovation Capital, JIC Venture Growth Investments, Japan Science and Technology Agency, and Remiges Ventures. New investors such as Astellas Venture Management, Ajinomoto, Shionogi, Co., Ltd., and Japan Venture Capital also contributed to the round.

Focus on Gene Therapy Development

Restore Vision is pioneering the development of a gene therapy drug, RV-001, aimed at regenerating vision lost due to retinal diseases. The therapy involves introducing a light-sensor protein called "Chimera Rhodopsin" into retinal interneurons via an intravitreal injection using an AAV vector. This optogenetics-based treatment targets conditions like retinitis pigmentosa, where photoreceptors are no longer functional.

The company recently completed the first patient administration in a Phase I/II clinical trial at Keio University Hospital, marking a significant milestone as the world's first clinical trial of optogenetics gene therapy using Chimera Rhodopsin.

Allocation of Funds

The newly acquired funds will be directed towards several key areas:

  • Global Development: Continued global clinical development of RV-001.
  • Research and Development: Investment in research and development for RV-001 and a second pipeline.
  • Management and Personnel: Strengthening management systems and expanding the team to support ongoing and future projects.

Restore Vision's funding marks a significant step in its mission to advance the treatment of retinal diseases and improve the quality of life for those affected by vision loss. As the company progresses, it remains committed to its innovative approaches in the field of gene therapy.